Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.

Stephen Padilla, 22 Jun 2020
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.

CABG better than PCI in diabetic patients with multivessel CAD

Stephen Padilla
10 Sep 2020

Patients with multivessel coronary artery disease (CAD) and diabetes treated with coronary artery bypass grafting (CABG) have improved long-term mortality and freedom from major cardiovascular and cerebrovascular events (MACCEs) compared to those treated with percutaneous coronary intervention (PCI), according to a study.

“CABG should be considered the preferred approach in patients with diabetes and multivessel CAD who are good surgical candidates,” the researchers said.

Records of diabetic patients with angiographic evidence 2- or 3-vessel CAD who were treated with either PCI or isolated CABG from 2008 to 2017 were obtained by linking clinical and administrative databases in Ontario, Canada. Baseline differences were accounted for by performing a propensity score match.

The researchers used a stratified log-rank test and Cox proportional hazards model to compare all-cause mortality and the composite of myocardial infarction (MI), repeat revascularization, stroke, or death (MACCEs) between the matched groups.

Overall, 4,519 patients underwent PCI and 9,716 CABG. Prior to matching, patients in the CABG group were significantly younger (mean age, 65.7 vs 68.3 years), were more likely to be men (78 percent vs 73 percent), and had more severe CAD. Propensity score matching based on 23 baseline covariates yielded 4,301 well-balanced pairs. [J Am Coll Cardiol 2020;76:1153-1164]

After matching, no difference in early mortality was found between PCI and CABG (2.4 percent vs 2.3 percent; p=0.721). The median and maximum follow-ups were 5.5 and 11.5 years, respectively.

Patients in the PCI group had significantly higher all-cause mortality (hazard ratio [HR], 1.39, 95 percent confidence interval [CI], 1.28–1.51) and overall MACCEs (HR, 1.99, 95 percent CI, 1.86–2.12) than those in the CABG group.

“Overall, these findings suggested that in patients with diabetes and multivessel CAD, revascularization with CABG might be the preferred approach,” the researchers said.

“Our analysis also found significant reductions in MI and need for repeat revascularization events in the CABG cohort, which was consistent with findings from the FREEDOM trial and the diabetic subgroup of the SYNTAX trial,” they added. [Lancet Diabetes Endocrinol 2013;1:317-328]

The varying mechanisms of PCI and CABG in the revascularization of diseased vessel might explain these findings. In PCI, stents are placed to treat focal flow limiting lesions, while any distal nonflow limiting lesions are left untreated. In CABG, however, the bypass graft is often placed distal to both the limiting and nonflow limiting lesions, the researchers explained. [J Am Coll Cardiol 2019;73:964-976]

Several studies have also found a twofold increase in the risk of stent restenosis in patients with diabetes compared with those without. Therefore, diabetic patients are more likely to experience MI and repeat revascularization. [Lancet 2007;369:667-678; J Am Coll Cardiol 2007;50:501-508]

In addition, there appears to be more incomplete revascularization with PCI than with CABG, according to the researchers. Studies have shown that incomplete revascularization leads to worse late survival and higher late MACCEs. [Interact Cardiovasc Thorac Surg 2014;18:679-682; Circulation 2016;133:2132-2140]

“Further work is warranted to ensure that patients with diabetes with extensive CAD are treated within a heart team framework,” the researchers noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.

Stephen Padilla, 22 Jun 2020
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.